Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. 2006

Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
Molecular Interactions Group, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Australia.

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA. NNRTIs, in particular, those that are potent inhibitors of RT polymerase activity, can also act as chemical enhancers of the enzyme's inter-subunit interactions. However, the consequences of this chemical enhancement effect on HIV-1 replication are not understood. Here, we show that the potent NNRTIs efavirenz, TMC120, and TMC125, but not nevirapine or delavirdine, inhibit the late stages of HIV-1 replication. These potent NNRTIs enhanced the intracellular processing of Gag and Gag-Pol polyproteins, and this was associated with a decrease in viral particle production from HIV-1-transfected cells. The increased polyprotein processing is consistent with premature activation of the HIV-1 protease by NNRTI-enhanced Gag-Pol multimerization through the embedded RT sequence. These findings support the view that Gag-Pol multimerization is an important step in viral assembly and demonstrate that regulation of Gag-Pol/Gag-Pol interactions is a novel target for small molecule inhibitors of HIV-1 production. Furthermore, these drugs can serve as useful probes to further understand processes involved in HIV-1 particle assembly and maturation.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
June 2009, Journal of medicinal chemistry,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
January 1996, Biochemistry,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
January 1996, Methods in enzymology,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
April 2023, Communications chemistry,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
October 1997, AIDS clinical care,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
January 2006, Current pharmaceutical design,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
February 1995, Science (New York, N.Y.),
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
June 2001, Proceedings of the National Academy of Sciences of the United States of America,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
February 1999, GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies,
Anna Figueiredo, and Katie L Moore, and Johnson Mak, and Nicolas Sluis-Cremer, and Marie-Pierre de Bethune, and Gilda Tachedjian
March 2013, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!